Plan Your Retatrutide Journey Model your dosing schedule, track your progress, and understand the pharmacokinetics with our free tools
GLP-1s by year and indication GLP-1s by indication and year GLP-1 pipeline FAQs (Wegovy) for SC administration for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), for use in combination with a reduced calorie diet and increased physical activity
If Willow lifestyle support gap has been your primary concern, the GLP-90 program may address it, but verify the specific coaching deliverables before committing $1,197 over three months
More recently, NICE Technology Appraisal TA875 has supported the use of semaglutide 2.4 mg (Wegovy) within specific criteria, including a BMI of 35 kg/m or above (or lower in certain high-risk groups) with at least one weight-related comorbidity
Gather all supplies within reach
Retatrutide achieved up to 24.2% mean weight loss after 48 weeks in individuals with obesity and 16.9% in those with T2D after 36 weeks